Clinical trials: Bleeding Diathesis
Haemophilia B
A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B
The purpose of this study is: to compare the pharmacokinetics of Replenine®-VF and Replenine® or any other high purity Factor IX concentrate, when given as a bolus dose of 75IU/kg.
- Trial name
- NCT02263456
- Testing
- Replenine®-VF (High Purity Factor IX)
- Where
- 7 sites in United Kingdom
- Sponsor
- Bio Products Laboratory
Hemophilia
The Effect of Functional Activities and Balance Ability With Taping in Subjects of Hemophilia
Background Hemophilia is a sex-linked genetic disorders. When the joint or the muscles is bleeding, it may cause haemarthrosis, synovium, cartilage tissue thickening, joint activity (Range of Motion) decreasing and other…
- Trial name
- NCT02389205
- Testing
- kinesio group
- Volunteers
- 30 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Haemophilia B
A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years
The objective of this study was to assess the safety and efficacy of Replenine®-VF in children enrolled in the study, under the age of six years, with severe haemophilia B.
- Trial name
- NCT02263469
- Testing
- Replenine®-VF (High Purity Factor IX)
- Where
- 4 sites in Poland, Ukraine
- Sponsor
- Bio Products Laboratory
Immune Thrombocytopenia
Caffeic Acid Tablets as a Second-line Therapy for ITP
The investigators are undertaking a multicentre, randomised controlled trial of 120 adults with newly diagnosed ITP from 5 medical centers in China.
- Trial name
- NCT02351622
- Testing
- Caffeic acid, Dexamethasone
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Shandong University
Hemophilia A, Congenital Factor VIII (FVIII) Deficiency
ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)
This is a Post-Authorization Safety Surveillance (PASS) study designed to collect data on the safety and effectiveness of ADVATE reconstituted in 2 mL Sterile water for injection (SWFI) during routine clinical practice in…
- Trial name
- NCT02093741
- Testing
- Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]
- Where
- 17 sites in France, Germany and 2 more
- Volunteers
- 65 people
- Sponsor
- Baxalta now part of Shire
Hemophilia A
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
C3731003 is a pivotal Phase 3 study to evaluate the clinical efficacy and safety of a single IV infusion of PF-07055480 / giroctocogene fitelparvovec (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in adult male participants…
- Trial name
- AFFINE (NCT04370054)
- Testing
- PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
- Where
- 45 sites in United States, Australia and 14 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
Shock Hemorrhagic
Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopathy Treatment (PREHO-PLYO)
In severe bleeding due to trauma, a decrease in coagulation factors maintains and promotes bleeding. The plasma allows, through its contribution of coagulation factors, early prevention or correction of this post-trauma induced…
- Trial name
- PREHO-PLYO (NCT02736812)
- Testing
- French Lyophilized Plasma, Normale Saline Solution
- Where
- 22 sites in France
- Volunteers
- 140 people
- Sponsor
- French Defence Health Service
Hemophilia A
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
Primary Objective: To evaluate the long-term safety of BIVV001 in previously treated subjects with hemophilia A Secondary Objectives: To evaluate the efficacy of BIVV001 as a prophylaxis treatment.
- Trial name
- XTEND-ed (NCT04644575)
- Testing
- efanesoctocog alfa (BIVV001)
- Where
- 85 sites in United States, Argentina and 21 more
- Volunteers
- 261 people
- Sponsor
- Bioverativ, a Sanofi company
Hemostatic Disorder
Hemostatic Disorders on Intensive Care Patients.
1. To assess the incidence of hemostatic disorders among ICU patients. 2. To establish a relationship between supportive treatment and survival in patients with coagulopathy in ICU. 3.
- Trial name
- NCT04179357
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Von Willebrand Disease
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
The main objective of the study is to compare the pharmacokinetics of Optivate® with the subject's current FVIII concentrate when given as a bolus dose of 50IU/kg.
- Trial name
- NCT02246881
- Testing
- Optivate® (Human Coagulation Factor VIII)
- Where
- 8 sites in Poland, United Kingdom
- Sponsor
- Bio Products Laboratory
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00630994
- Testing
- Dacogen
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Hemophilia
A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or B
The purpose of this non-interventional, observational, real-world study is to find out what are the real-world experiences of people living with hemophilia A or B[OK1.1] who start the study medicine (called marstacimab) in…
- Trial name
- NCT07859527
- Testing
- Marstacimab
- Volunteers
- 100 people
- Sponsor
- Pfizer
Ecchymosis After Periorbital Rejuvenation With Botulinum Toxin Type A, Crow's Feet Lines
A Real-World Study on Effect of Hirudoid on Ecchymosis After Treatment of Crow's Feet With Botulinum Toxin Type A
Botulinum toxin type A (commonly referred to as 'Botox') injections are a treatment that dermatologists regularly use to smoothen wrinkles such as 'Crow's feet', to rejuvenate the skin surrounding the eye (the 'periorbital…
- Conditions
- Ecchymosis After Periorbital Rejuvenation With Botulinum Toxin Type A, Crow's Feet Lines, Lateral Canthal Lines, LCL
- Trial name
- NCT07388927
- Testing
- Hirudoid (heparinoids) ointment, 3mg/g
- Volunteers
- 48 people
- Sponsor
- DKSH Management (Thailand) Limited
Hemophilia
Validity and Reliability of the Figure-of-Eight Walking and Weight-Bearing Lunge Tests in Hemophilia
Recurrent joint bleeding (hemarthrosis) occurs in 70-80% of cases of hemophilia. The three most frequently affected joints are the synovial joints of the ankle, knee, and elbow.
- Trial name
- NCT07851922
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Yuzuncu Yil University
Hemophilia
Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
The purpose of this study is to investigate the safety of a test drug to treat hemophilia in adult men.
- Trial name
- NCT03996486
- Testing
- BAY1093884
- Sponsor
- Bayer
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Hemophilia B
Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
This is a Phase 1, open- label, non- randomized, uncontrolled, single dose pilot study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of BBM-H901 in hemophilia B subjects with ≤2IU/dl residual…
- Trial name
- NCT05709288
- Testing
- BBM-H901
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Von Willebrand Diseases, Hemophilia A
BT200 in Hereditary Bleeding Disorders
BT200 is a PEGylated aptamer that binds to the A1 domain of human von Willebrand factor (VWF). At low doses, BT200 blocks the clearance of VWF antigen (VWF Ag) from the circulation and causes an increase in concentrations of both…
- Trial name
- NCT04677803
- Testing
- BT200
- Where
- Austria
- Volunteers
- 26 people
- Sponsor
- Medical University of Vienna
Coagulation Disorder
Comparison of Two Point-of-care Devices for Viscoelastic Hemostasis Assays
This study will investigate the correlation and agreement of Quantra-derived parameters with parameters reported by the ROTEM delta and standard laboratory tests in cardiac surgery patients.
- Trial name
- NCT03685097
- Testing
- Quantra System with the QPlus Cartridge
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- HemoSonics LLC
Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
The purpose of this study is to determine the efficacy, safety and tolerability, of AKR-501 (avatrombopag) tablets, as compared to placebo, in the treatment of participants with chronic Idiopathic Thrombocytopenic Purpura (ITP).
- Trial name
- NCT00441090
- Testing
- Avatrombopag tablets
- Where
- 25 sites in United States
- Volunteers
- 64 people
- Sponsor
- Eisai Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.